Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Proto-Oncogene Drgu market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.2% during the forecast period.
This report presents the market size and development trends by detailing the Proto-Oncogene Drgu market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Proto-Oncogene Drgu market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Proto-Oncogene Drgu industry and will help you to build a panoramic view of the industrial development.
Proto-Oncogene Drgu Market, By Type:
Axitinib (Inlyta)
Ponatinib (Iclusig)
Imatinib (Gleevec)
Sunitinib (Sutent)
Pazopanib (Votrient)
Dabrafenib (Tafinlar)
Vandetanib (Caprelsa)
Vemurafenib (Zelboraf)
Cabozantinib (Cabometyx and Cometriq)
Sorafenib (Nexavar)
Proto-Oncogene Drgu Market, By Application:
Clinic
Hospital
Others
Some of the leading players are as follows:
ARIAD Pharmaceuticals
Exelixis
Bayer Healthcare
ChemGenex Pharmaceuticals
Onyx Pharmaceuticals
Pfizer
Novartis
Bristol-Myers Squibb
Dexa Medica
Eisai Pharmaceuticals
AstraZeneca
Plexxikon
GlaxoSmithKline
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Proto-Oncogene Drgu Market: Technology Type Analysis
-
4.1 Proto-Oncogene Drgu Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Proto-Oncogene Drgu Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Axitinib (Inlyta)
4.3.2 Ponatinib (Iclusig)
4.3.3 Imatinib (Gleevec)
4.3.4 Sunitinib (Sutent)
4.3.5 Pazopanib (Votrient)
4.3.6 Dabrafenib (Tafinlar)
4.3.7 Vandetanib (Caprelsa)
4.3.8 Vemurafenib (Zelboraf)
4.3.9 Cabozantinib (Cabometyx and Cometriq)
4.3.10 Sorafenib (Nexavar)
5 Proto-Oncogene Drgu Market: Product Analysis
-
5.1 Proto-Oncogene Drgu Product Market Share Analysis, 2018 & 2026
-
5.2 Proto-Oncogene Drgu Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Proto-Oncogene Drgu Market: Application Analysis
-
6.1 Proto-Oncogene Drgu Application Market Share Analysis, 2018 & 2026
-
6.2 Proto-Oncogene Drgu Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Clinic
6.3.2 Hospital
6.3.3 Others
7 Proto-Oncogene Drgu Market: Regional Analysis
-
7.1 Proto-Oncogene Drgu Regional Market Share Analysis, 2018 & 2026
-
7.2 Proto-Oncogene Drgu Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 ARIAD Pharmaceuticals
9.1.1 ARIAD Pharmaceuticals Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Exelixis
9.2.1 Exelixis Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Bayer Healthcare
9.3.1 Bayer Healthcare Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 ChemGenex Pharmaceuticals
9.4.1 ChemGenex Pharmaceuticals Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Onyx Pharmaceuticals
9.5.1 Onyx Pharmaceuticals Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Pfizer
9.6.1 Pfizer Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Novartis
9.7.1 Novartis Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Bristol-Myers Squibb
9.8.1 Bristol-Myers Squibb Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Dexa Medica
9.9.1 Dexa Medica Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Eisai Pharmaceuticals
9.10.1 Eisai Pharmaceuticals Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 AstraZeneca
9.11.1 AstraZeneca Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Plexxikon
9.12.1 Plexxikon Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 GlaxoSmithKline
9.13.1 GlaxoSmithKline Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
The List of Tables and Figures (Totals 97 Figures and 155 Tables)
Figure Axitinib (Inlyta) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Ponatinib (Iclusig) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Imatinib (Gleevec) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Sunitinib (Sutent) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Pazopanib (Votrient) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Dabrafenib (Tafinlar) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Vandetanib (Caprelsa) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Vemurafenib (Zelboraf) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Cabozantinib (Cabometyx and Cometriq) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Sorafenib (Nexavar) Proto-Oncogene Drgu market, 2015 - 2026 (USD Million)
Figure Clinic market, 2015 - 2026 (USD Million)
Figure Hospital market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Proto-Oncogene Drgu market, by country, 2015 - 2026 (USD Million)
-
Table North America Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table North America Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table North America Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Canada Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Canada Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Europe Proto-Oncogene Drgu market, by country, 2015 - 2026 (USD Million)
-
Table Europe Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Europe Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Europe Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Germany Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Germany Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table France Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table France Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Italy Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Italy Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Spain Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Spain Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Proto-Oncogene Drgu market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table China Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table China Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Japan Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Japan Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table India Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table India Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Proto-Oncogene Drgu market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table MEA Proto-Oncogene Drgu market, by country, 2015 - 2026 (USD Million)
-
Table MEA Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table MEA Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table MEA Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Proto-Oncogene Drgu market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Proto-Oncogene Drgu market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Proto-Oncogene Drgu market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table ARIAD Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Exelixis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer Healthcare Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table ChemGenex Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Onyx Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dexa Medica Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eisai Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Plexxikon Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
